Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Non Operating Income (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Non Operating Income for 16 consecutive years, with -$1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income fell 151.69% to -$1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$8.5 million, a 525.89% decrease, with the full-year FY2024 number at -$5.5 million, down 2302.64% from a year prior.
  • Non Operating Income was -$1.3 million for Q3 2025 at Harvard Bioscience, up from -$1.4 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.8 million in Q4 2023 to a low of -$4.6 million in Q4 2024.
  • A 5-year average of -$425157.9 and a median of -$313000.0 in 2021 define the central range for Non Operating Income.
  • Biggest YoY gain for Non Operating Income was 5622.22% in 2024; the steepest drop was 610.42% in 2024.
  • Harvard Bioscience's Non Operating Income stood at -$189000.0 in 2021, then crashed by 130.16% to -$435000.0 in 2022, then soared by 752.41% to $2.8 million in 2023, then tumbled by 262.54% to -$4.6 million in 2024, then soared by 71.15% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Non Operating Income are -$1.3 million (Q3 2025), -$1.4 million (Q2 2025), and -$1.1 million (Q1 2025).